

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 October 2022 (13.10.2022)



(10) International Publication Number
WO 2022/216580 A1

(51) International Patent Classification:
C07K 16/30 (2006.01)

(21) International Application Number:
PCT/US2022/023250

(22) International Filing Date:
04 April 2022 (04.04.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/172,299 08 April 2021 (08.04.2021) US

(71) Applicant: **MERCK SHARP & DOHME LLC** [US/US];
126 East Lincoln Avenue, Rahway, New Jersey 07065 (US).

(72) Inventors; and

(71) Applicants (for US only): **LALA, Mallika** [IN/US]; 126
East Lincoln Avenue, Rahway, New Jersey 07065-0907
(US). **DE MIRANDA SILVA, Carolina** [BR/US]; 126

East Lincoln Avenue, Rahway, New Jersey 07065-0907
(US). **GHEYAS, Ferdous** [US/US]; 126 East Lincoln Ave-
nue, Rahway, New Jersey 07065-0907 (US). **KRISHNA-
MACHARI, Yogita** [US/US]; 2000 Galloping Hill Road,
Kenilworth, New Jersey 07033 (US). **CHARTASH, Elliot
Keith** [US/US]; 126 East Lincoln Avenue, Rahway, New
Jersey 07065-0907 (US). **JAIN, Lokesh** [US/US]; 12 Deb-
orah Drive, Edison, New Jersey 08820 (US). **VADDADY,
Venkata Naga Ratna Pavan Kumar** [IN/US]; 4737 Abra-
ham Freed Road, Doylestown, Pennsylvania 18902 (US).

(74) Common Representative: **MERCK SHARP & DOHME
LLC**; 126 East Lincoln Avenue, Rahway, New Jersey
07065 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,

(54) Title: METHODS FOR TREATING CANCER WITH SUBCUTANEOUS ADMINISTRATION OF ANTI-PD1 ANTIBODIES




FIG.2

(57) Abstract: The invention relates to methods for treating cancer in a patient comprising subcutaneously administering a PD-1 antagonist, e.g., an anti-PD-1 antibody, or antigen binding fragment thereof, (e.g. pembrolizumab), in specific amounts to the patient. In some embodiments, the administration occurs about every three weeks. In some embodiments, the amount of anti-PD-1 antibody, or antigen binding fragment thereof, is about 280 mg to about 450 mg. In certain embodiments, the PD-1 antagonist is pembrolizumab, or an antigen binding fragment thereof. Also provided are compositions and kits formulated for subcutaneous administration comprising a dosage of an anti-PD-1 antibody, or antigen-binding fragment thereof, and uses thereof for treating cancer.

[Continued on next page]



WO 2022/216580 A1

KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*